• Reimagining Plant Protein Stability: Integrating m6A Insight

  2026-06-19

  Explore how cutting-edge mechanistic research on RNA m6A modification and host-pathogen interactions informs next-generation preservation of plant protein integrity. This article connects the latest molecular findings with translational workflow strategy, demonstrating how broad-spectrum inhibitors such as the APExBIO Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) enable robust protein stabilization in plant research and emerging applications.

• Ceftazidime in Respiratory Infection Research: Resistance, D

  2026-06-19

  Explore the multifaceted role of Ceftazidime, a third-generation cephalosporin, in advancing respiratory infection research. This article uniquely analyzes resistance dynamics and practical assay choices, delivering actionable insights for scientists confronting the evolving landscape of Gram-negative pathogens.

• BV6 IAP Antagonist: Precision Tools for Apoptosis Research

  2026-06-18

  BV6, a selective IAP antagonist from APExBIO, enables reliable induction of apoptosis and radiosensitization in cancer and disease models. This guide details experimental workflows, protocol enhancements, and troubleshooting strategies to maximize reproducibility and translational impact.

• L-Alanyl-L-Glutamine: Technical Guide for Intestinal Barrier

  2026-06-18

  L-Alanyl-L-Glutamine (SKU B8228) addresses instability and poor solubility limitations of standard glutamine in protocols requiring intestinal mucosa protection and antioxidant system support. It should be applied where water solubility and reliable delivery are necessary, but is not suitable for use in organic solvents or for long-term solution storage.

• Fumagillin: Bridging Tumor Angiogenesis and Parasitology Inn

  2026-06-17

  This thought-leadership article explores the mechanistic foundation and translational impact of Fumagillin, a methionine aminopeptidase-2 inhibitor, in both cancer and aquatic parasitology research. By integrating evidence from recent peer-reviewed studies and highlighting APExBIO’s role in delivering research-grade Fumagillin, the article offers actionable guidance for translational scientists navigating complex angiogenesis and antiparasitic models.

• Applied Workflows with (-)-Blebbistatin: Precision in Cytosk

  2026-06-17

  (-)-Blebbistatin, a selective non-muscle myosin II inhibitor from APExBIO, enables high-fidelity dissection of actin-myosin interactions in cell adhesion, migration, and cardiac contractility studies. This article translates bench-proven workflows and troubleshooting strategies into actionable protocols for advanced cytoskeletal dynamics research.

• Serine/Glycine-Free Diet Modulates CRC Immunity via PD-L1 La

  2026-06-16

  This study demonstrates that a serine/glycine-free diet suppresses colorectal cancer (CRC) growth and enhances antitumor immunity, but also promotes immune evasion through PD-L1 lactylation. The findings provide mechanistic insights into metabolic-immune interactions and support the diet’s clinical feasibility as an adjunct to immunotherapy.

• KNUCKLES Orchestrates Floral Meristem Termination via Auxin

  2026-06-16

  This study uncovers how the transcriptional repressor KNUCKLES (KNU) integrates hormonal signaling to ensure timely floral meristem (FM) termination in Arabidopsis, revealing direct epigenetic repression of auxin transporter and cytokinin biosynthesis genes. These insights refine the molecular framework for FM determinacy and highlight new mechanistic parallels for developmental regulation.

• CTP Solution Empowers High-Fidelity RNA Synthesis Workflows

  2026-06-15

  CTP Solution (100 mM) by APExBIO delivers unmatched reliability as a nucleotide substrate for advanced in vitro transcription and mRNA-LNP therapeutics. Its high purity and enzyme-free formulation are pivotal for reproducible RNA synthesis and tumor suppressor mRNA delivery, as highlighted in pioneering bladder cancer research.

• Z-Ligustilide and Cisplatin: Targeting PLPP1 to Overcome Lun

  2026-06-15

  This study demonstrates that combining Z-ligustilide with cisplatin impairs cisplatin resistance in lung cancer by decreasing PLPP1-mediated phospholipid synthesis. Multi-omics analysis reveals this combination induces cell cycle arrest and apoptosis in resistant lung cancer cells, offering a mechanistically substantiated approach for overcoming chemoresistance.

• Transmission of Carbapenemase Genes in CREC: Insights from G

  2026-06-14

  This study characterizes the prevalence and dynamics of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight hospitals in Guangdong, China. The findings reveal the dominance of plasmid-borne blaNDM-1 and extensive multidrug resistance, emphasizing the urgent need for molecular surveillance and tailored antimicrobial strategies.

• Cleavage-Resistant TREM2 Enhances Macrophage Efferocytosis i

  2026-06-13

  Dong et al. introduce a synthetic, cleavage-resistant TREM2 variant (CRT) that resists ADAM17-mediated shedding and restores efferocytosis in inflamed tissues. Their lipid nanoparticle mRNA delivery strategy generates CRT-expressing macrophages in situ, reducing apoptotic cell accumulation and inflammation in disease models, with broad implications for treating chronic inflammatory disorders.

• FITC-Concanavalin A (ConA) Conjugate: Technical Application

  2026-06-12

  FITC-Concanavalin A (ConA) Conjugate provides a direct, fluorescence-based method for detecting α-D-glucose and α-D-mannose residues on cell surfaces, addressing key needs in immunofluorescence and flow cytometry carbohydrate assays. It should not be used for non-glycan targets or outside the defined storage and handling parameters.

• VX-702: Advancing p38α MAPK Inhibition for Translational Suc

  2026-06-12

  This article provides mechanistic clarity and actionable guidance for translational researchers leveraging VX-702, a next-generation p38α MAPK inhibitor. Integrating the latest structural insights and practical workflow recommendations, it explores VX-702’s role in robust cytokine suppression, disease modeling, and pathway deconvolution, while addressing its unique advantages versus traditional kinase inhibitors.

• Propranolol Alters Metabolic Pathways to Improve Burn Outcom

  2026-06-11

  A phase II randomized trial demonstrates that propranolol profoundly remodels adipose tissue metabolism in severely burned patients, normalizing metabolomic and lipidomic profiles and reducing inflammatory and catabolic responses. These findings yield mechanistic insight into how beta-blockade improves clinical outcomes after burn and guide future metabolic intervention strategies.

406 records 11/28 page Previous Next First page 上5页 1112131415 下5页 Last page